Resistant or Refractory Solid Tumors

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Calgent Biotechnology
Calgent BiotechnologyTaiwan - Taipei City
1 program
1
CAL056 mesylatePhase 11 trial
Active Trials
NCT04686383CompletedEst. Jun 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Calgent BiotechnologyCAL056 mesylate

Clinical Trials (1)

NCT04686383Calgent BiotechnologyCAL056 mesylate

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Start: Dec 2020Est. completion: Jun 2022
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2m ago

Office Administrator

SystImmune
2m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
13m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
16m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
16m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)